semaglutide hidradenitis suppurativa The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects Emerging Role of GLP-1 Receptor
Description
Coppenrath V, Mazyck B
In the Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose of retatrutide achieved an average body weight reduction of 24.2% over 48 weeks
It ran for 68 weeks (n=445
[DOI] [PMC free article] [PubMed] [Google Scholar] [235].Jirapinyo P, Jin DX, Qazi T, Mishra N, Thompson CC (2018)
If Wegovy becomes covered under Part D for a specific indication, Medigap would not apply - Part D has its own cost-sharing structure
